Evidence map›Paper›PMID 35543528›Full record

ArticleParasite (Paris, France)2022

Monitoring the elimination of gambiense human African trypanosomiasis in the historical focus of Batié, South-West Burkina Faso.

Charlie Franck Alfred Compaoré, Jacques Kaboré, Hamidou Ilboudo, Lian Francesca Thomas, Laura Cristina Falzon, Mohamed Bamba, Hassane Sakande, Minayégninrin Koné, Dramane Kaba, Clarisse Bougouma and 7 more

Registry-linked trialAbstract read
In one paragraph

Article in Parasite (Paris, France), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06356974 (An Intervention Study to Evaluate the Impact of Treating gHAT Seropositive Subjects With Acoziborole on Transmission of T.b. Gambiense, and Obtain Further Safety Data on Acoziborole in gHAT Seropositive Individuals), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06356974 phase3not yet recruitingnot on this mapstarted 2024, after this paper: background citation

An Intervention Study to Evaluate the Impact of Treating gHAT Seropositive Subjects With Acoziborole on Transmission of T.b. Gambiense, and Obtain Further Safety Data on Acoziborole in gHAT Seropositive Individuals

TypeinterventionalSponsorDrugs for Neglected DiseasesRan2024 to 2027Enrolled2,500ConditionsHuman African TrypanosomiasisArmsTreatment of seropositive individuals (positive serology test, but parasitology not confirmed)
3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Trial
  2. Article
  3. Observational
  4. Review
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Charlie Franck Alfred CompaoréCentre International de Recherche-Développement sur l'Élevage en zone Subhumide, Unité de recherche sur les maladies à vecteurs et biodiversité, 01 BP 454 Bobo-Dioulasso 01, Burkina Faso - Université Nazi Boni, Unité de Formation et de Recherche Sciences et Techniques, 01 BP 1091 Bobo-Dioulasso, Burkina-Faso.
Jacques KaboréCentre International de Recherche-Développement sur l'Élevage en zone Subhumide, Unité de recherche sur les maladies à vecteurs et biodiversité, 01 BP 454 Bobo-Dioulasso 01, Burkina Faso - Université Nazi Boni, Unité de Formation et de Recherche Sciences et Techniques, 01 BP 1091 Bobo-Dioulasso, Burkina-Faso.
Hamidou IlboudoInstitut de Recherche en Sciences de la Santé, Unité de Recherche Clinique de Nanoro, 11 BP 218 Ouagadougou CMS 11, Burkina Faso.
Lian Francesca ThomasInternational Livestock Research Institute, PO Box 30709, Nairobi 00100, Kenya - University of Liverpool, Institute of Infection, Veterinary and Ecological Sciences, Liverpool L69 3BX, United Kingdom.
Laura Cristina FalzonInternational Livestock Research Institute, PO Box 30709, Nairobi 00100, Kenya - University of Liverpool, Institute of Infection, Veterinary and Ecological Sciences, Liverpool L69 3BX, United Kingdom.
Mohamed BambaCentre International de Recherche-Développement sur l'Élevage en zone Subhumide, Unité de recherche sur les maladies à vecteurs et biodiversité, 01 BP 454 Bobo-Dioulasso 01, Burkina Faso.
Hassane SakandeCentre International de Recherche-Développement sur l'Élevage en zone Subhumide, Unité de recherche sur les maladies à vecteurs et biodiversité, 01 BP 454 Bobo-Dioulasso 01, Burkina Faso.
Minayégninrin KonéInstitut Pierre Richet, Unité de Recherche et de Formation Trypanosomoses et Leishmanioses, 01 BP 1500 Bouake, Côte d'Ivoire.
Dramane KabaInstitut Pierre Richet, Unité de Recherche et de Formation Trypanosomoses et Leishmanioses, 01 BP 1500 Bouake, Côte d'Ivoire.
Clarisse BougoumaProgramme National de Lutte contre les Maladies Tropicales Négligées, 03 BP 7009 Ouagadougou 03, Burkina Faso.
Ilboudo AdamaProgramme National de Lutte contre les Maladies Tropicales Négligées, 03 BP 7009 Ouagadougou 03, Burkina Faso.
Ouedraogo AmatheProgramme National de Lutte contre les Maladies Tropicales Négligées, 03 BP 7009 Ouagadougou 03, Burkina Faso.
Adrien Marie Gaston BelemUniversité Nazi Boni, Unité de Formation et de Recherche Sciences et Techniques, 01 BP 1091 Bobo-Dioulasso, Burkina-Faso.
Eric Maurice FèvreInternational Livestock Research Institute, PO Box 30709, Nairobi 00100, Kenya - University of Liverpool, Institute of Infection, Veterinary and Ecological Sciences, Liverpool L69 3BX, United Kingdom.
Philippe BüscherInstitute of Tropical Medicine, Department of Biomedical Sciences, Nationalestraat 155, 2000 Antwerp, Belgium.
Veerle LejonInstitut de Recherche pour le Développement, UMR INTERTRYP IRD-CIRAD, Université de Montpellier, TA A-17/G, Campus International de Baillarguet, 34398 Montpellier, France.
Vincent JamonneauInstitut Pierre Richet, Unité de Recherche et de Formation Trypanosomoses et Leishmanioses, 01 BP 1500 Bouake, Côte d'Ivoire - Institut de Recherche pour le Développement, UMR INTERTRYP IRD-CIRAD, Université de Montpellier, TA A-17/G, Campus International de Baillarguet, 34398 Montpellier, France.ORCID 0000-0001-8427-0769

Funding

EDCTP2 Programme supported by the European Union Project DRIA-2014-306-DiTECT-HAT
6 · The paper itself

Abstract

The World Health Organisation has targeted the elimination of human African trypanosomiasis (HAT) as zero transmission by 2030. Continued surveillance needs to be in place for early detection of re-emergent cases. In this context, the performance of diagnostic tests and testing algorithms for detection of the re-emergence of Trypanosoma brucei gambiense HAT remains to be assessed. We carried out a door-to-door active medical survey for HAT in the historical focus of Batié, South-West Burkina Faso. Screening was done using three rapid diagnostic tests (RDTs). Two laboratory tests (ELISA/T. b. gambiense and immune trypanolysis) and parasitological examination were performed on RDT positives only. In total, 5883 participants were screened, among which 842 (14%) tested positive in at least one RDT. Blood from 519 RDT positives was examined microscopically but no trypanosomes were observed. The HAT Sero-K-Set test showed the lowest specificity of 89%, while the specificities of SD Bioline HAT and rHAT Sero-Strip were 92% and 99%, respectively. The specificity of ELISA/T. b. gambiense and trypanolysis was 99% (98-99%) and 100% (99-100%), respectively. Our results suggest that T. b. gambiense is no longer circulating in the study area and that zero transmission has probably been attained. While a least cost analysis is still required, our study showed that RDT preselection followed by trypanolysis may be a useful strategy for post-elimination surveillance in Burkina Faso.

Indexed as

Trypanosomiasis, AfricanAlgorithmsAnimalsBurkina FasoHumansMass ScreeningTrypanosoma brucei gambienseBurkina FasoDiagnosisDried blood spotEliminationHuman African trypanosomiasisRapid diagnostic testSpecificityTrypanosoma brucei gambiense

Identifiers

PMID35543528
PMCPMC9093133

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.